Nektar Therapeutics (NKTR) Times Interest Earned (2010 - 2026)
Nektar Therapeutics (NKTR) posted quarterly Times Interest Earned of -$4.92 for Q1 2026, up 45.08% year-over-year from -$3.39 in Q1 2025, and down 73.64% quarter-over-quarter from -$2.83 in Q4 2025.
Nektar Therapeutics (NKTR) Times Interest Earned (2010 - 2026) Analysis & Trends
Nektar Therapeutics' Times Interest Earned history runs 17 years deep, the most recent figure standing at -$4.92 for Q1 2026.
- In Q1 2026, Times Interest Earned rose 45.08% year-over-year to -$4.92; the TTM figure through Mar 2026 stood at -$4.62 (down 11.32% YoY), while the FY2025 annual figure was -$0.16, down 28.2% from the prior year.
- Times Interest Earned for Q1 2026 stood at -$4.92, down from -$2.83 in the prior quarter.
- The five-year high for Times Interest Earned was $1.41 in Q4 2024, with the low at -$21.14 in Q2 2022.
- The 5-year median for Times Interest Earned is -$7.29 (2022), against an average of -$8.27.
- The sharpest annual moves came in 2024 and 2025: Times Interest Earned surged 128.96% in 2024, then sank 300.39% in 2025.
- Nektar Therapeutics' Times Interest Earned stood at -$7.29 in 2022, then jumped by 33.03% to -$4.88 in 2023, then soared by 128.96% to $1.41 in 2024, then tumbled by 300.39% to -$2.83 in 2025, then sank by 73.64% to -$4.92 in 2026.
- Business Quant data shows NKTR's Times Interest Earned at -$4.92 in Q1 2026, -$2.83 in Q4 2025, and -$5.24 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Nektar Therapeutics | 1.49 Bn | 919.46 Mn | 3.16 Mn | -4.92 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.92 |
| Dec 31, 2025 | -2.83 |
| Sep 30, 2025 | -5.24 |
| Jun 30, 2025 | -6.72 |
| Mar 31, 2025 | -8.95 |
| Dec 31, 2024 | 1.41 |
| Sep 30, 2024 | -5.71 |
| Jun 30, 2024 | -7.77 |
| Mar 31, 2024 | -6.41 |
| Dec 31, 2023 | -4.88 |
| Sep 30, 2023 | -7.59 |
| Jun 30, 2023 | -8.22 |
| Mar 31, 2023 | -21.03 |
| Dec 31, 2022 | -7.29 |
| Sep 30, 2022 | -7.81 |
| Jun 30, 2022 | -21.14 |
| Mar 31, 2022 | -15.48 |
| Dec 31, 2021 | 5.04 |
| Sep 30, 2021 | -8.87 |
| Jun 30, 2021 | -8.42 |